Market Research Logo

Metastatic Prostate Cancer - Pipeline Review, H1 2015

Metastatic Prostate Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Metastatic Prostate Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Metastatic Prostate Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Prostate Cancer - Overview
Pipeline Products for Metastatic Prostate Cancer - Comparative Analysis
Metastatic Prostate Cancer - Therapeutics under Development by Companies
Metastatic Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Prostate Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Prostate Cancer - Products under Development by Companies
Metastatic Prostate Cancer - Products under Investigation by Universities/Institutes
Metastatic Prostate Cancer - Companies Involved in Therapeutics Development
Actinium Pharmaceuticals, Inc.
Camurus AB
Colby Pharmaceutical Company
Eli Lilly and Company
Fountain Biopharma Inc.
Johnson & Johnson
MedImmune, LLC
MEI Pharma, Inc.
OncoMax
OXiGENE, Inc.
Progenics Pharmaceuticals, Inc.
ValiRx Plc
Metastatic Prostate Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abiraterone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimab-P - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CADD-522 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target PSMA for Metastatic Prostate Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPC-410 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FB-704A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KGP-94 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LU-901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-2495655 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-6469 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIP-1095 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MVI-118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMRCA-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Prostate Cancer - Recent Pipeline Updates
Metastatic Prostate Cancer - Dormant Projects
Metastatic Prostate Cancer - Discontinued Products
Metastatic Prostate Cancer - Product Development Milestones
Featured News & Press Releases
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
Feb 06, 2014: ZYTIGA Now Reimbursed in Québec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer
Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy
May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer
Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients
May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer
Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Prostate Cancer, H1 2015
Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Metastatic Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Metastatic Prostate Cancer - Pipeline by Camurus AB, H1 2015
Metastatic Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2015
Metastatic Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2015
Metastatic Prostate Cancer - Pipeline by Fountain Biopharma Inc., H1 2015
Metastatic Prostate Cancer - Pipeline by Johnson & Johnson, H1 2015
Metastatic Prostate Cancer - Pipeline by MedImmune, LLC, H1 2015
Metastatic Prostate Cancer - Pipeline by MEI Pharma, Inc., H1 2015
Metastatic Prostate Cancer - Pipeline by OncoMax, H1 2015
Metastatic Prostate Cancer - Pipeline by OXiGENE, Inc., H1 2015
Metastatic Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015
Metastatic Prostate Cancer - Pipeline by ValiRx Plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Metastatic Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Metastatic Prostate Cancer - Dormant Projects, H1 2015
Metastatic Prostate Cancer - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Metastatic Prostate Cancer, H1 2015
Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report